Conexeu Sciences Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of novel therapies for patients facing complex and life-threatening conditions. Operating primarily in the United States and listed on the NASDAQ, the company focuses on leveraging advanced biological insights and proprietary technology platforms to build a robust pipeline of drug candidates. Conexeu Sciences operates within the healthcare sector, specifically targeting the biotechnology and life sciences industry group. Its research and development efforts are centered on identifying unique biological pathways to treat diseases in areas such as oncology, inflammatory disorders, and other specialized therapeutic fields. The company's strategy involves advancing its candidates through rigorous clinical trials while seeking strategic partnerships to accelerate the delivery of its innovations to the global market. By prioritizing precision medicine and high-impact therapeutic areas, Conexeu Sciences aims to improve patient outcomes and provide value to its stakeholders. The company is led by a team of experienced professionals in the biopharmaceutical space who are committed to scientific excellence and the advancement of next-generation medical treatments.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!